Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 57

Results For "acquisition"

572 News Found

Meddo acquires Doxper in a cash and stock deal
Healthcare | August 03, 2021

Meddo acquires Doxper in a cash and stock deal

This deal makes Meddo, one of the largest health-tech players in India


IPCA Laboratories increases stake in Trophic Wellness to 52.35%
News | June 12, 2021

IPCA Laboratories increases stake in Trophic Wellness to 52.35%

With the acquisition of these further shares, TWPL has now become company's subsidiary.


Bayer acquires Noria and PSMA Therapeutics
News | June 07, 2021

Bayer acquires Noria and PSMA Therapeutics

Broadens company’s oncology platform of Targeted Alpha Therapies (TATs)


Progress on new ventures key for Aurobindo Pharma: ICICI Securities
News | June 02, 2021

Progress on new ventures key for Aurobindo Pharma: ICICI Securities

Aurobindo has one of the most enduring generics ecosystems among peers


Outlook intact for Dr. Reddy's Laboratories : ICICI Securities
News | May 18, 2021

Outlook intact for Dr. Reddy's Laboratories : ICICI Securities

India sales grew 23.5% YoY with consolidation of Wockhardt products


Aceto acquires specialty exipients company A&C
News | April 16, 2021

Aceto acquires specialty exipients company A&C

Acquisition of A&C expands Aceto’s Western manufacturing footprint


Piramal Enterprises forays into peptide with Hemmo Pharma : ICICI Securities
News | April 05, 2021

Piramal Enterprises forays into peptide with Hemmo Pharma : ICICI Securities

ICICI Securities expects Hemmo to grow its revenue at a CAGR of 30.0% over FY21E-FY23E


Piramal Pharma to acquire 100% stake in Hemmo for Rs 775 Cr
News | April 01, 2021

Piramal Pharma to acquire 100% stake in Hemmo for Rs 775 Cr

This acquisition marks PPS’ foray into the development and manufacturing of peptide APIs


Bayer delivers robust performance despite pandemic
News | February 26, 2021

Bayer delivers robust performance despite pandemic

The company expects to generate an EBITDA margin before special items of around 27 percent in 2021.


WACKER acquires plasmid DNA Manufacturer Genopis
News | February 05, 2021

WACKER acquires plasmid DNA Manufacturer Genopis

WACKER and Helixmith plan to strategically collaborate on the production of a pDNA gene therapy developed by Helixmith for the treatment of diabetic peripheral neuropathy (DPN).